ClinicalTrials.govpublic full text
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
multiple myeloma, mor03087 (mor202), lenalidomide, pomalidomide, cd38, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 895610
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.